clinical trials
-
Research updates, October 7
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
-
Research updates, September 30
Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.
-
Research updates, September 23
Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.
-
Still Here, September 19: Links and transcript
In this episode of Still Here, the finale of our season 1 ends the way it started, with a recap of the latest RECOVER-TLC workshop.
-
Research updates, September 16
An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.
-
Stop looking for a silver bullet. Start mixing the Long COVID cocktail.
Here’s what keeps me up at night: If some people are finding relief, why aren’t we scaling what might work? And why aren’t we trying multiple interventions at the same time?
-
RECOVER-TLC announces new Long COVID clinical trials, receives mixed reactions from patient community
Some Long COVID advocates and researchers, including those who advised the National Institutes of Health’s initiative, say RECOVER-TLC isn’t living up to its promised ambition.
-
Live blog: RECOVER-TLC workshop on new Long COVID clinical trials
Researchers and advocates meet near the National Institutes of Health (NIH) campus this week in Bethesda, Maryland for the second RECOVER-Treating Long COVID (TLC) workshop. The two-day event will offer updates on the NIH’s larger $1.8-billion Long COVID research program, called RECOVER, and announce a new set of clinical trials for the disease.
-
Research updates, September 2
Metformin may help reduce the risk of Long COVID, according to two new studies. One large study from the United Kingdom found that it reduced the rate of Long COVID in “obese and overweight” people by 63% percent.
-
Still Here, August 22: Links and transcript
In this episode of Still Here: Betsy Ladyzhets and Miles Griffis recap the Keystone Symposia. Plus, a recap of a new NIH RECOVER preprint about reinfections.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance